Control of Disease Activity with Large Extended-Interval Dosing of Rituximab/ocrelizumab in Highly Active Pediatric Multiple Sclerosis.
MULTIPLE SCLEROSIS JOURNAL(2024)
Key words
Pediatric onset multiple sclerosis,ocrelizumab,rituximab
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined